Progressing from Clinical Validation to Best-in-Class Claudin-Targeted Therapeutics

The 2024 approval of Astellas’ zolbetuximab in Japan, the first ever approval against claudin 18.2, has cemented the clinical validation of claudin proteins as effective anti-cancer target.  

 As oncology biopharma continue to invest in claudin targeted pipelines, the timely 1st Annual Claudin-Targeted Therapies Summit is the world’s only claudin-focused meeting offering comprehensive insights into claudin-targeted development across discovery, preclinical development, through to emerging clinical performance.  

 With content representing all therapeutic modalities across CLDN18.2, CLDN6, CLDN1 and beyond, this is your must attend meeting showcasing Zolbetuximab and other cutting-edge clinical development of novel claudin therapies revolutionizing oncology, delving into innovative claudin modality development and toxicity management approaches, and exploring claudin biology and ensure translational success to advance the next wave of claudin-targeted therapies. 

Don’t miss your chance to join 50+ pioneering Claudin industry leaders from the likes of Astellas, AstraZeneca, Innovent Biologics, Triumvira Immunologics, Xencor, and Alentis Therapeutics to unlock cutting-edge claudin therapy development, competitive insights, and networking to position your claudin candidates for success in one of oncology’s hottest targets.